Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Keywords:
Área de Medicina Clínica y Epidemiología
Trastuzumab deruxtecan (T-DXd)
Metastatic colorectal cancer (mCRC)
Objective response rate (ORR)
Note:
This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
Citation:
Yoshino, T.; Di Bartolomeo, M.; Raghav, K.; et al. "Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer". Nature communications. 14 (1), 2023, 3332
Statistics and impact
0 citas en
![Web of knowledge](/image/dadun/item/web_of_knowledge-logo.png)
0 citas en
![Scopus](/image/dadun/item/scopus-logo.png)
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.